The Arabic medication-related burden quality of life (MRB-QoL) tool: Cross-cultural adaptation and content validation

被引:0
|
作者
Al-Ebrahim, Sundos Q. [1 ]
Harrison, Jeff [1 ]
Chen, Timothy F. [2 ]
Alzubaidi, Hamzah [3 ]
Mohammed, Mohammed A. [1 ]
机构
[1] Univ Auckland, Fac Med & Hlth Sci, Sch Pharm, Private Bag 92019, Auckland 1142, New Zealand
[2] Univ Sydney, Fac Pharm, Sydney, NSW, Australia
[3] Univ Sharjah, Coll Pharm, Sharjah, U Arab Emirates
关键词
Medication-related burden; Quality of life; Translation; Cultural adaptation; Cross-cultural adaptation; Arabic; Delphi; Cognitive debriefing; Content validity; TERM MEDICINES USE; CONTENT VALIDITY; PSYCHOLOGICAL-ASSESSMENT; PSYCHOMETRIC VALIDATION; PHARMACEUTICAL THERAPY; INSTRUMENT; CARE; OUTCOMES; TRANSLATION; VERSION;
D O I
10.1016/j.rcsop.2024.100523
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The Medication-Related Burden Quality of Life (MRB-QoL) is a 31-item valid and reliable patientreported measure of medicine burden on functioning and well-being in people with long-term conditions (LTC). Objectives: To translate, culturally adapt, and content validate the MRB-QoL into Arabic. Methods: A rigorous approach to cross-cultural adaptation proposed by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guideline was followed. After 3 forward translations and 2 backward translations, a multidisciplinary expert panel assessed the content validity (CV) of the items through a 2-round e-modified Delphi method followed by two-step cognitive debriefings with patients with LTC using think-aloud and probing techniques. An item-content validity index (I-CVI) score of >= 0.78 was considered acceptable. The original questionnaire developers and other researchers, as members of the review committee, reviewed and approved the Arabic version. Results: Five semantic and 3 cultural translation discrepancies were identified and resolved by rewording the items. The 2 backward translations did not reveal significant problems, and equivalence to the original tool was confirmed following committee review. The Arabic version showed acceptable CV parameters. E-modified Delphi involved 9 experts in round one and 7 in round 2. The I-CVI scores ranged from 0.67 to 1.0, and agreement was reached after 2 rounds. The CVI for the final version of the MRB-QoL was 0.96. Expert panel review showed that the MRB-QoL-Arabic version is relevant (CVI = 0.92), important (CVI = 0.97), clear (CVI = 0.98), and comprehensive in measuring the burden of medicines. Data from 5 cognitive interviews showed that items and concepts included in the Arabic version of the MRB-QoL are relevant to the targeted sample, clear, and easy to understand. Conclusion: The MRB-QoL Arabic version was developed and content validated. However, further evaluation of its other psychometric properties is necessary before it can be utilized in clinical and research settings. Using this tool will enable a more accurate understanding of the effects of treatment burden on patient well-being, thereby guiding care toward minimally disruptive medicine.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The Medication-Related Burden Quality of Life (MRB-QoL) tool: A confirmatory factor analysis of the Arabic version
    Al-Ebrahim, Sundos Q.
    Hafidh, Khadija
    Jallo, Mahir
    Mauwfak, Mais M.
    Nassef, Mohamed
    Alzubaidi, Hamzah
    Harrison, Jeff
    Chen, Timothy F.
    Mohammed, Mohammed A.
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2025, 17
  • [2] Development and validation of an instrument for measuring the burden of medicine on functioning and wellbeing: the Medication-Related Burden Quality of Life (MRB-QoL) tool
    Mohammed, Mohammed A.
    Moles, Rebekah J.
    Hilmer, Sarah N.
    O'Donnel, Lisa Kouladjian
    Chen, Timothy F.
    BMJ OPEN, 2018, 8 (01):
  • [3] Factors Associated with Medication-Related Burden Quality of Life (MRB-QoL) in Community-Dwelling Adults with Long-Term Conditions: An Exploratory Study
    Mohammed, Mohammed A.
    Moles, Rebekah J.
    Chen, Timothy F.
    PATIENT-RELATED OUTCOME MEASURES, 2021, 12 : 55 - 63
  • [4] Cross-cultural adaptation and validation of Systemic Lupus Erythematosus Quality of Life questionnaire into Arabic
    Aziz, M. M.
    Galal, M. A. A.
    Elzohri, M. H.
    El-Nouby, F.
    Leong, K. P.
    LUPUS, 2018, 27 (05) : 780 - 787
  • [5] Cross-Cultural Adaptation and Validation of the Voice-Related Quality of Life Into Persian
    Moradi, Negin
    Saki, Nader
    Aghadoost, Ozra
    Nikakhlagh, Soheila
    Soltani, Majid
    Derakhshandeh, Vita
    Naderifar, Ehsan
    Bakhtiari, Behrooz Mahmoodi
    Javadipour, Shiva
    JOURNAL OF VOICE, 2014, 28 (06) : 842.e1 - 842.e9
  • [6] The Creation of the Arabic Version of the Hyperhidrosis Quality of Life Index (HidroQoL©) with Validation and Cross-Cultural Adaptation
    Almuhaideb, Qais A.
    Abudujain, Nasser M.
    Alghamdi, Khalid M.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2025, 18 : 251 - 263
  • [7] Cross-Cultural Adaptation and Validation of the Arabic Version of the Prolapse Quality of Life Questionnaire in the United Arab Emirates
    Alzarooni, Asma Abdelrahman
    Shousha, Tamer Mohamed
    Kim, Meeyoung
    HEALTHCARE, 2024, 12 (04)
  • [8] Cross-cultural adaptation and validation of the Arabic version of McGill quality of life: revised questionnaire in the patients with cancer
    Omar, Mohammed T. A.
    Al-Malki, Majed Hassan
    Bindawas, Saad M.
    Alnahdi, Ali H.
    Aljehan, Ghaidaa H.
    Al-Omar, Badr Nasser
    Alhammad, Saad A.
    DISABILITY AND REHABILITATION, 2024, 46 (09) : 1878 - 1887
  • [9] CROSS-CULTURAL VALIDATION OF A QUALITY-OF-LIFE (QOL) SCALE FOR DRUG STUDIES
    LURIE, A
    CHWALOW, J
    BEAN, K
    DUCHATELET, IP
    VENOT, A
    DOUCOT, Y
    STRAUCH, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 127 - 127
  • [10] Cross-Cultural Adaptation, Translation and Validation of Kannada Version of the Swallowing Quality of Life Questionnaire (KSWAL-QOL)
    Chandrashekaraiah, Bilvashree
    Swapna, N.
    Belliappa, M. Sonam
    INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2024, 76 (01) : 351 - 357